New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
05:58 EDTNUAN, MRKStocks with implied volatility movement; NUAN MRK
Stocks with implied volatility movement; Nuance (NUAN), Merck (MRK) according to iVolatility.
News For NUAN;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 17, 2015
10:48 EDTNUANNuance rises after earnings as analysts point to bookings as positive sign
Shares of Nuance Communications (NUAN) climbed in morning trading after analysts from Deutsche Bank and Oppenheimer raised their price targets on the company following upbeat fourth quarter earnings. WHAT'S NEW: After the market close yesterday, Nuance reported Q4 earnings per share of 41c, beating analyst estimates of 35c, on revenue of $504.1M, just short of consensus $507.84M. The company provided guidance for fiscal 2016, saying it expects earnings per share for the year in the range of $1.35-$1.45 on revenue of $1.95B-$2B. Nuance also said it expects first quarter EPS of 31c-33c on revenue of $477.8M-$489.8M. WHAT'S NOTABLE: In the same press release, Nuance chief financial officer Dan Tempesta said that the company has made "substantial progress" on its company-wide transformation project. "We expect to continue our improvements in financial performance and lead the company to improved growth in 2016 and beyond," Tempesta said. STREET RESEARCH: Following the quarterly report, Deutsche Bank analyst Nandan Amladi maintained a Buy rating on the company's stock and raised its price target to $30 from $25, citing greater visibility from recurring revenue. Amladi said that Nuance had a "robust" finish to fiscal 2015 and that bookings and recurring revenue metrics were stronger than traditional licenses. The analyst added that the company's outlook leaves some headroom for upside and that its buyback activity should continue its "pronounced" pace heading into FY16. In addition, Oppenheimer analyst Shaul Eyal maintained an Outperform rating on Nuance and raised the price target on the company's shares to $26 from $22, saying that the company's shift towards a more software-as-a-service focused business model shows positive indications. Eyal added that the company's fundamentals are improving and that EPS accretion is supported by an ongoing share repurchase and cost containment measures. PRICE ACTION: In morning trading, Nuance rallied 14.5% to $19.53. OTHERS TO WATCH: Philips (PHG), which reached a collaboration agreement with Nuance a month ago to provide Nuance users its PowerScribe 360 software, was up 1.4% in morning trading.
10:02 EDTNUANHigh option volume stocks
Subscribe for More Information
09:15 EDTNUANOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.1%... Cheetah Mobile (CMCM), up 7.7%... Eros International (EROS), up 12.8%... Home Depot (HD), up 3.1%...Wal-Mart (WMT), up 2.2%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 14.8% after announcing Phase 1 study results for the company's oral formulation of OCR-002... Fitbit (FIT), up 2.4% after being upgraded to Buy from Neutral at BofA/Merrill. DOWN AFTER EARNINGS: Dicks Sporting Goods (DKS), down 15.4%... Urban Outfitters (URBN), down 12.8%. ALSO LOWER: Osiris Therapeutics (OSIR), up 25.5% after being downgraded to Sell from Hold at Brean Capital... Angie's List (ANGI), down 8.7% after board unanimously determines not to pursue IAC (IACI) proposal... Clovis Oncology (CLVS), down 4.1% after receiving downgrades from Goldman and WallachBeth... Chesapeake Energy (CHK), down 2.5% after being downgraded to Neutral from Buy at Sterne Agee CRT... Cooper Companies (COO), down 2% after being downgraded to Market Perform from Outperform at Wells Fargo.
08:04 EDTMRKMerck to present new KEYTRUDA findings at upcoming congresses
Merck announced that data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. In total, data from more than 30 abstracts will be presented at the Society for Melanoma Research 2015 Congress in San Francisco, Nov. 18 - 21; the 57th American Society of Hematology Annual Meeting in Orlando, Florida, Dec. 5 - 8; the San Antonio Breast Cancer Symposium, Dec. 8 - 12; and the European Society for Medical Oncology Asia 2015 Congress in Singapore, Dec. 18 - 21. By the end of 2015, data on the anti-tumor activity of KEYTRUDA will have been presented across more than 20 tumor types. "The field of immuno-oncology holds great potential across a broad spectrum of cancers," said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories. "Data for KEYTRUDA being presented at these scientific meetings include a first-time comparison to chemotherapy in advanced non-small cell lung cancer, novel combination data in advanced melanoma as well as first-time data in two additional tumor types, namely multiple myeloma and hormone receptor positive breast cancer, further demonstrating our deep commitment to advancing cancer treatment."
07:55 EDTNUANNuance price target raised to $26 from $22 at Oppenheimer
Subscribe for More Information
06:36 EDTNUANNuance price target raised to $30 from $25 at Deutsche Bank
Subscribe for More Information
November 16, 2015
18:26 EDTNUANOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.5%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 26.6% after announcing Phase 1 study results for the company's oral formulation of OCR-002. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 11.5%... Agilent (A), down 1.3%. ALSO LOWER: Wayfair (W), down 2% after Bloomberg reported that Whitney Tilson said that Wayfair is currently his largest short.
16:15 EDTNUANNuance sees Q1 EPS 31c-33c, consensus 31c
Sees Q1 GAAP revenue $477.8M-$489.8M, consensus $490.62M. Sees Q1 Non-GAAP revenue $486M-$498M.
16:13 EDTNUANNuance sees FY16 EPS $1.35-$1.45 consensus $1.38
Subscribe for More Information
16:04 EDTNUANNuance reports Q4 EPS 41c, consensus 35c
Reports Q4 revenue $504.1M, consensus $507.84M. In the fourth quarter of fiscal 2015, Nuance reported GAAP revenue of $504.1M up from $502.3M a year ago. Nuance reported non-GAAP revenue of $513.3M, which includes $9.2M of revenue lost to accounting treatment in conjunction with acquisitions, compared to $520.3M in the fourth quarter of fiscal 2014. Fourth quarter 2015 revenue was negatively affected by currency fluctuations as well. If fourth quarter 2014 currency rates were applied to fourth quarter 2015 non-GAAP revenue, Nuance would have achieved approximately 1% organic non-GAAP revenue growth for the quarter. In the fourth quarter of 2015, total recurring revenue was $347M and represented 68% of total non-GAAP revenue, compared to $325.7M and 63% a year ago. In the fourth quarter of fiscal 2015, Nuance reported net new bookings of $357.4M, up 8.7% from $328.8M a year ago. If fourth quarter 2014 currency rates were applied to Nuance's fourth quarter 2015, net new bookings would have been up 12% from a year ago.
15:02 EDTNUANNotable companies reporting after market close
Subscribe for More Information
13:38 EDTNUANNuance technical comments ahead of results
The stock has been trading in a range since September of this year that is defined largely by a low at $16 and a high at $17.75. If the news is bullish, there could be a breakout above the top of the range. Next resistance levels above $17.75 are at $18.49, $18.96, which is the 52-week high, and $19.39. If the news is a negative surprise, there could be a break of the low of the range. Next supports below $16 would be at $15.21, $14.60, and $14.
08:35 EDTMRKMerck to present Phase 2 hep C therapy data at The Liver Meeting
Subscribe for More Information
07:24 EDTMRKSalomon to hold a conference
Subscribe for More Information
November 15, 2015
15:19 EDTMRKMerck reports integrated analysis of six trials of elbasvir/grazoprevir
Subscribe for More Information
15:15 EDTMRKMerck reports Phase 3 data on elbasvir/grazoprevir in patients injecting drugs
Subscribe for More Information
November 13, 2015
08:02 EDTMRKMerck: DMC recommends anacetrapib study continue with no changes
Subscribe for More Information
06:11 EDTNUANNuance volatility elevated into Q4 and outlook
Nuance November call option implied volatility is at 67, December is at 40, January is at 37; compared to its 52-week range of 21 to 51, suggesting large near term price movement into the expected release of Q4 results on November 16.
November 12, 2015
17:02 EDTMRKMerck Animal Health to Acquire Harrisvaccines
Merck Animal Health and Harrisvaccines announced the companies have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals. The terms of the agreement were not disclosed. The companies expect the transaction to close in the fourth quarter of 2015.
11:50 EDTMRKMerck issues statement regarding CUBICIN patent litigation
Merck issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit: "The decision validated the patent for CUBICIN that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020. The company is reviewing the decision and is considering its next steps, which may include seeking further review at the Federal Circuit or Supreme Court."
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use